Lytix Biopharma AS – Mandatory notification of trade by Primary Insiders and close associates

25 Apr 2024 17:13 CEST

Oslo, Norway, 25 April 2024: Reference is made to the stock exchange
announcements published by Lytix Biopharma AS ("Lytix" or the "Company") earlier
today, on 25 April 2024, regarding the final results of the partially guaranteed
share offering (the "Offering").

As of this date, the Company has been informed that the following primary
insiders and close associates to primary insiders have been allocated new shares
in the Offering, as set out below:

Hifo Invest AS, a close associate to primary insider, Brynjar Forbergsskog,
subscribed for 724,448.00 shares in the Offering. Hifo Invest AS was allocated
724,448.00 shares at a price of NOK 5.24 per share.

Saturn Invest AS, a close associate to primary insider, Brynjar Forbergsskog,
subscribed for 724,448.00 shares in the Offering. Saturn Invest AS was allocated
724,448.00 shares at a price of NOK 5.24 per share.

Øystein Rekdal, primary insider, subscribed for 9,550.00 shares in the Offering.
Øystein Rekdal was allocated 9,550.00 shares at a price of NOK 5.24 per share.

Gjest Andreas Breistein, primary insider, subscribed for 10,000.00 shares in the
Offering. Gjest Andreas Breistein was allocated 10,000.00 shares at a price of
NOK 5.24 per share.

Baldur Sveinbjørnsson, primary insider, subscribed for 4,000.00 shares in the
Offering. Baldur Sveinbjørnsson was allocated 4,000.00 shares at a price of NOK
5.24 per share.

Please see the attached forms for further details about the transactions.

Disclosure regulation:

This information is subject to the disclosure requirements pursuant to article
19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian
Securities Trading Act.

For more information, please contact:
Gjest Breistein, CFO
+47 952 60 512
gjest.breistein@lytixbiopharma.com

About Lytix:
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with
a highly novel technology based on world leading research in host-defense
peptide-derived molecules. Lytix Biopharma’s lead product, LTX-315, is a
first-in-class oncolytic molecule representing a new principle to boost
anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that can work
in many different cancer indications and treatment settings, both as mono- and
combination therapy.

More information:
Access the news on Oslo Bors NewsWeb site

616907_Lytix - Mandatory notifications of trade.pdf